USWM-AP2-3000: A Phase 3, Open-Label Study of the Safety, Efficacy, and Tolerability of Apopmorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients with Unsatisfactory Control on Available Therapy

August 17, 2018
https://clinicaltrials.gov/ct2/show/NCT02339064
Parkinson Disease
Principal Investigator: Peter A Le Witt, MD
Parkinson's Disease, PD, Advanced Parkinson's Disease, Apomorphone, Parkinsons Disease
Accepting Participants
(248)661-6540